CN112553297A - Specific primer combination, kit and method for quickly detecting methylation of human miR-34a gene - Google Patents
Specific primer combination, kit and method for quickly detecting methylation of human miR-34a gene Download PDFInfo
- Publication number
- CN112553297A CN112553297A CN202011642978.XA CN202011642978A CN112553297A CN 112553297 A CN112553297 A CN 112553297A CN 202011642978 A CN202011642978 A CN 202011642978A CN 112553297 A CN112553297 A CN 112553297A
- Authority
- CN
- China
- Prior art keywords
- methylation
- specific primer
- solution
- digoxin
- human mir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000011987 methylation Effects 0.000 title claims abstract description 89
- 238000007069 methylation reaction Methods 0.000 title claims abstract description 89
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 38
- 108091029119 miR-34a stem-loop Proteins 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000001514 detection method Methods 0.000 claims abstract description 62
- 230000003321 amplification Effects 0.000 claims abstract description 47
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 47
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims abstract description 35
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims abstract description 35
- 229960005156 digoxin Drugs 0.000 claims abstract description 35
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims abstract description 35
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000010931 gold Substances 0.000 claims abstract description 9
- 229910052737 gold Inorganic materials 0.000 claims abstract description 9
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 4
- 238000012360 testing method Methods 0.000 claims description 51
- 108020004414 DNA Proteins 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 37
- 239000006249 magnetic particle Substances 0.000 claims description 20
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 150000002343 gold Chemical class 0.000 claims description 13
- 210000005259 peripheral blood Anatomy 0.000 claims description 10
- 239000011886 peripheral blood Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 229960002685 biotin Drugs 0.000 claims description 9
- 235000020958 biotin Nutrition 0.000 claims description 9
- 239000011616 biotin Substances 0.000 claims description 9
- 210000002700 urine Anatomy 0.000 claims description 9
- 238000003908 quality control method Methods 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 108010090804 Streptavidin Proteins 0.000 claims description 7
- 238000011161 development Methods 0.000 claims description 7
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 6
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 5
- 239000012266 salt solution Substances 0.000 claims description 5
- 239000011246 composite particle Substances 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 claims description 3
- 239000011258 core-shell material Substances 0.000 claims description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical group C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 claims description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 claims description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 claims description 3
- 229910000342 sodium bisulfate Inorganic materials 0.000 claims description 3
- 229940035893 uracil Drugs 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 2
- JVXNCJLLOUQYBF-UHFFFAOYSA-N cyclohex-4-ene-1,3-dione Chemical compound O=C1CC=CC(=O)C1 JVXNCJLLOUQYBF-UHFFFAOYSA-N 0.000 claims description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 claims description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 2
- 235000010265 sodium sulphite Nutrition 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 abstract description 10
- 150000007523 nucleic acids Chemical class 0.000 abstract description 10
- 102000039446 nucleic acids Human genes 0.000 abstract description 10
- 230000007067 DNA methylation Effects 0.000 abstract description 8
- 230000035945 sensitivity Effects 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 7
- 239000000539 dimer Substances 0.000 abstract description 3
- 239000012634 fragment Substances 0.000 abstract description 2
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 239000002122 magnetic nanoparticle Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000006607 hypermethylation Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- -1 dDTP Chemical compound 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a specific primer combination, a kit and a method for quickly detecting human miR-34a gene methylation. The method comprises the steps of converting DNA methylation differences of samples collected by the method into DNA sequence differences; based on the principle of LAMP nucleic acid amplification and primer mismatching amplification block, the identification of DNA sequence difference is realized in the LAMP reaction process; the rapid detection of the methylation of the specific gene is realized by utilizing mutual recognition and coupling of the digoxin marked on the amplified fragment and the digoxin monoclonal antibody marked on the surface of the gold magnetic nanoparticle and combining a lateral flow chromatography technology. The invention uses LAMP technology to amplify nucleic acid, greatly shortens the time of nucleic acid amplification, reduces the dependence on instrument and equipment, and improves the sensitivity; the detection of the amplification product thoroughly avoids the false positive phenomenon caused by primer dimer, and improves the specificity; the problems of high cost, time consumption, labor consumption and the like caused by the identification of nucleic acid amplification products are saved, so that the detection method is easier to popularize.
Description
Technical Field
The invention belongs to the technical field of gene methylation detection, and particularly relates to a specific primer combination, a kit and a method for quickly detecting human miR-34a gene methylation.
Background
Cancer poses a serious threat to human health on a global scale and is the leading cause of human disease death. The main bases for cancer diagnosis include clinical symptoms, imaging detection, histopathological examination, etc., and the clinical symptoms of many cancer patients appear later, and most early cancer patients do not have any obvious clinical symptoms. For early screening of cancer, many methods are currently included, such as low-dose CT diagnosis, tissue-cell-level cancer diagnosis, and gene-level cancer diagnosis. However, these approaches have a number of disadvantages: the low-dose CT detection has the problem of false positive and high detection cost; tissue-level cancer diagnosis can cause great pain to the patient in terms of sampling and may lead to cancer cell spreading or metastasis; the detection of tumor specific molecular markers at the gene level can be used as a means for early diagnosis of cancer, but the technology is not mature.
Currently, methods for genetic detection of diseases are receiving wide attention. DNA methylation is an important component of epigenetics, not only maintaining normal cellular function, but also playing an important role in carcinogenesis, and alteration of methylation status is an important factor in causing cancer. The DNA methylation is adopted as a marker for disease diagnosis, and the advantages are mainly as follows: firstly, in the process of tumor formation, the occurrence frequency of promoter hypermethylation is very high, even higher than that of gene mutation, and important genes related to tumor formation are not lacked; secondly, methylation is an important event in the early stages of tumorigenesis; thirdly, DNA methylation exists stably, and detection can be carried out through a gene amplification effect. Therefore, methylation detection has potential application value in early diagnosis of tumors.
Although the prior art has found a plurality of cancer-related methylated genes, in early cancers, the methylation frequency of different genes and the hypermethylation sites of different genes are different, and the applicable detection method needs further research. In peripheral blood, DNA with abnormal methylation only accounts for about 0.1% -1% of the total DNA, and the unmethylated DNA and methylated DNA have only slight difference, so that trace abnormal methylated DNA needs to be detected from a highly complex interference background, and the detection method is highly required. In addition, methylation detection at the laboratory level is highly dependent on sophisticated instrumentation and tedious procedures of professionals, severely hampering the spread of individualized medicine in the context of precision medicine. Therefore, it is necessary to provide a rapid, sensitive and convenient means for detecting gene methylation, which is of great significance in early screening and popularization of cancer.
Disclosure of Invention
The invention provides a specific primer combination, a kit and a method for quickly detecting human miR-34a gene methylation, and mainly solves the problems that the existing method can only be limited to laboratory application, the detection cost is high, and quick and sensitive detection cannot be realized.
The specific technical solution of the invention is as follows:
the specific primer combination for quickly detecting the methylation of the human miR-34a gene comprises a methylation specific primer group and an unmethylated specific primer group,
the nucleotide sequences of the methylation specific primer sets are as follows:
the nucleotide sequence of the upstream inner primer FIP in the methylation specific primer group is as follows:
5'-biotin-CACGTGAAATTTATTGCGTTGGAGGTCCGTTAGTGCGATGTACCC
the nucleotide sequence of the downstream inner primer BIP in the methylation specific primer group is as follows:
5'-biotin-ATTGCAAAAATCCAAGAAGCAGCGAGATGTGCCAATCACATAA
the nucleotide sequence of the upstream outer primer F3 in the methylation specific primer group is as follows:
GGAGAAAGTGTTGGAGGGTGAA
the nucleotide sequence of the downstream outer primer B3 in the methylation specific primer group is as follows:
ACTCAAACTAACCATATCACAACA；
the nucleotide sequence of the upstream inner primer FIP in the unmethylated specific primer group is as follows:
5'-biotin-ACATTAAAACATTACATCAATCGAGGGTTACCGATTAATCCTAGAATGTAAG
the nucleotide sequence of the downstream inner primer BIP in the unmethylated specific primer group is as follows:
5'-biotin-AAATAACCAAACTGGAATTGAACTTATGTGTTAGAAATGTCAAATGTGGTT
the nucleotide sequence of the upstream outer primer F3 in the unmethylated specific primer group is as follows: GGTGGAGAGAATTTGAGGAGGA
The nucleotide sequence of the downstream outer primer B3 in the unmethylated specific primer group is as follows: CTAAACCCAACTAACATACATCAA are provided.
The kit for quickly detecting the methylation of the human miR-34a gene by applying the specific primer group comprises a specific primer combination and a test strip.
Furthermore, a quality control line of the test strip is sprayed with goat anti-rabbit IgG for quality control, a detection line is sprayed with streptavidin for capture, and a binding pad is sprayed with digoxin monoclonal antibody modified gold magnetic particles.
Further, the digoxin monoclonal antibody modified gold magnetic particles are superparamagnetic composite particles with a core-shell structure, the core of the digoxin monoclonal antibody modified gold magnetic particles is nano Fe3O4 magnetic particles, the surface of the core is a gold shell layer, and the surface of the gold is modified with digoxin monoclonal antibody to form digoxin monoclonal antibody modified gold magnetic particles.
Furthermore, the base of digoxin label in digoxin monoclonal antibody modified on the surface of the gold is dATP, dTTP, dCTP, dDTP or dUTP.
A rapid detection method for human miR-34a gene methylation is characterized by comprising the following steps:
1, obtaining a tissue genome DNA and/or an episome DNA sample;
2, modifying the DNA sample obtained in the step 1 to convert unmethylated cytosine into uracil, wherein the methylated cytosine is not changed;
performing two LAMP reactions in parallel on any sample treated in the step 2, wherein the methylation specific primer group is used in one reaction, and the unmethylated specific primer is used in the other reaction;
adding bases marked by digoxin into two LAMP reaction systems of the same sample to mark amplification products, wherein the two LAMP reaction systems have the same reaction conditions and are simultaneously placed under the constant temperature condition to obtain the amplification products;
and 5, rapidly detecting the amplification product obtained by the treatment in the step 4 by using the test strip in the kit for rapidly detecting the human miR-34a gene methylation, and judging the methylation mode of the sample.
Further, in the step 1), the free DNA sample is free DNA of peripheral blood, free DNA of urine or free DNA of other tissue fluids.
Further, in the step 2), the modification liquid is an inorganic salt solution or an organic solution with the concentration of 5 mM-5M.
Further, the inorganic salt solution or the organic solution is a KOH solution, a NaOH solution, a Ca (OH)2 solution, a NaHSO3 solution, a NaHSO4 solution, a Na2SO3 solution or a C6H6O2 solution.
Further, the step 5 specifically includes:
dropping the two tubes of amplification products completing the same sample in the step 4 onto sample pads of two test strips respectively for detection, wherein the obtained amplification products are labeled with biotin and digoxin simultaneously, after dropping the amplification products onto the sample pads, the digoxin on the amplification products is specifically combined with the digoxin monoclonal antibody modified gold magnetic particles, and moving up to the detection line in a chromatography manner, the biotin on the amplification products is specifically combined with streptavidin on the detection line for color development, while the reaction solution amplified by the non-methylated specific primers is not developed on the detection line of the test strips, so that complete methylation is indicated; otherwise, the methylation is not carried out; if the detection lines of the two test strips are colored, partial methylation is indicated.
The beneficial effects of the invention are embodied in the following aspects:
(1) reduce the detection cost and is convenient for popularization and use
The existing detection technologies for DNA methylation, such as fluorescence quantitative PCR, gene chip hybridization, PCR combined with gel electrophoresis, PCR combined with capillary electrophoresis, PCR combined with enzymatic cleavage, DNA direct sequencing, etc., usually require some special instruments, such as gene sequencer, chip spotting instrument, fluorescence quantitative PCR, electrophoresis and imaging equipment, etc., or require complicated enzyme treatment of amplification products, which requires high cost to complete detection. The invention not only saves the cost of the DNA purification reagent, but also does not need special instruments and equipment, and only visualizes the interpretation result through the test paper strip, thereby greatly reducing the whole detection cost and being convenient for popularization and use in all levels of medical institutions.
(2) Improving the detection sensitivity
Compared with the existing methylation detection method based on PCR, the method adopts LAMP nucleic acid amplification technology, obtains high sensitivity while ensuring accuracy and operation simplicity by optimizing conditions such as primers and an LAMP reaction system, and can still accurately detect trace target sequences when the proportion of the target sequences in the total detection template is 0.1%.
(3) Improving detection specificity
Existing methods for detecting DNA methylation based on nucleic acid amplification lead to serious false positives due to primer dimer factors when the primer concentration is increased in order to increase the sensitivity of detection. When the DNA methylation detection kit is used for DNA methylation detection, only one biomarker oligonucleotide participates in amplification reaction, and even if primer dimer is generated, color development on a chromatographic test strip cannot be caused to further cause misjudgment. The design of the invention enables the detection method to have high sensitivity and simultaneously maintain high specificity.
(4) Improve the detection efficiency
Most of the existing techniques based on nucleic acid amplification rely on PCR methods, but the PCR-dependent methods require thermal cycling and the whole nucleic acid amplification process takes up to 90 min. The LAMP nucleic acid amplification technology is adopted, so that the nucleic acid amplification process can be finished in an isothermal environment for 30min without thermal cycle, and the detection efficiency is greatly improved.
Drawings
FIG. 1 is a schematic diagram showing the color development result of a test strip when the methylation mode of the present invention is complete methylation;
FIG. 2 is a schematic diagram showing the color development of the test strip when the methylation pattern is unmethylated in accordance with the present invention;
FIG. 3 is a schematic diagram showing the color development of the test strip when the methylation pattern is partial methylation according to the present invention;
Detailed Description
The present invention is further described in detail below with reference to the attached drawings so that those skilled in the art can implement the invention by referring to the description text.
The invention provides a rapid detection method for human miR-34a gene methylation, which comprises the following steps:
1 ] obtaining a sample: the sample type may be tissue genomic DNA, peripheral blood free DNA, urine free DNA, or other tissue fluid free DNA.
Processing of the sample: the DNA obtained in the first step needs to be treated by a set of modification solution so that unmethylated cytosine is converted into uracil and methylated cytosine is not changed.
Performing two LAMP reactions in parallel aiming at each sample, wherein one reaction uses a methylation specific primer, and the other reaction uses an unmethylated specific primer; the specific primers are mainly designed aiming at a promoter and a first exon region of a miR-34a gene to be detected, and a group of methylation specific primers and a group of non-methylation specific primers are respectively designed for recognition and amplification; 5' -end labeled biotin is arranged on both FIP primers and BIP primers in the two groups of specific primers;
adding bases marked by digoxin into two LAMP reaction systems to mark amplification products, wherein the two LAMP reaction systems have the same reaction conditions and are simultaneously placed under the constant temperature condition to obtain the amplification products, and the amplification reaction systems are as follows:
and 5, rapidly detecting the amplification product obtained in the step 5 by using a chromatographic test strip and judging the methylation mode of the sample by using the specific visual characteristic of the gold magnetic particles, the action of digoxin and digoxin monoclonal antibody and the action of biotin and streptavidin by using a chromatographic technique. Dropwise adding a reaction solution amplified by the methylation specific primer to develop color on a detection line of the test strip, and indicating that the reaction solution amplified by the unmethylated specific primer does not develop color on the detection line of the test strip, so that complete methylation is indicated; otherwise, the methylation is not carried out; if the detection lines of the two test strips are colored, partial methylation is indicated.
Wherein, the sample type in the step one is tissue genome DNA, peripheral blood free DNA, urine free DNA or other tissue fluid free DNA.
The modification solution in step 2 is inorganic salt solution or organic solution of 5mM-5M, which may be KOH solution, NaOH solution, Ca (OH)2Solution, NaHSO3Solution, NaHSO4Solution, Na2SO3Solutions or C6H6O2And (3) solution.
The digoxin labeled base described in step 4 is dATP, dTTP, dCTP, dDTP, or dUTP.
The test paper strip adopted by the chromatography in the step 5 meets the following conditions:
a. the quality control line of the test strip is sprayed with goat anti-rabbit IgG for quality control;
b. streptavidin for capture is sprayed on the detection line of the test strip;
c. the combination pad of the test strip is sprayed with digoxin monoclonal antibody modified gold magnetic particles;
and 5, performing parting detection, namely dripping the two amplification products finished in the fifth step on sample pads of the two test strips respectively for detection. And marking biotin and digoxin on the obtained amplification product, after the obtained amplification product is dripped on a sample pad, specifically binding the digoxin and the digoxin monoclonal antibody coupled gold magnetic particles, moving the sample up to a detection line through chromatography, specifically binding the biotin on the amplification product and streptavidin on the detection line for color development, and judging the methylation mode of the sample according to the result.
The digoxin monoclonal antibody modified gold magnetic particle in the sixth step is a superparamagnetic composite particle with a core-shell structure, and the core of the superparamagnetic composite particle is nano Fe3O4The surface of the magnetic particle is a gold shell layer, and the surface of the gold is modified with digoxin monoclonal antibody to form digoxin monoclonal antibody modified gold magnetic particles.
The following examples illustrate the implementation process of the rapid detection method for human miR-34a gene methylation provided by the invention.
Example 1 design and optimization of primers
Designing primers aiming at a miR-34a gene promoter region and a first exon region: the gene sequence of miR-34a is confirmed by NCBI database, and synthetic primers are designed according to the gene sequence. Aiming at miR-34a gene to be detected, a group of methylation specific primers and a group of non-methylation specific primers are respectively designed for identification and amplification, and each group of primers is complementary with a corresponding template base. In order to facilitate the subsequent chromatographic detection technology, the designed primers and bases are subjected to biological labeling. Wherein FIP and BIP are labeled with biotin and bases are labeled with digoxigenin. In order to increase the amplification specificity and the detection resolution, a plurality of groups of primers are designed for experimental screening.
The optimal primers were screened according to the following targets: (1) the amplification specificity is high: the completely methylated and unmethylated specific primers can only amplify specific target bands for corresponding templates. (2) The amplification sensitivity is high, and the target fragment can be effectively amplified under the condition that as low as 0.1 percent of the target sequence exists in a sample. (3) The kit has high adaptability to sample types, is suitable for common genome DNA samples, and can effectively and specifically amplify free DNA of peripheral blood, free DNA of urine or free DNA of other tissue fluids.
Wherein, for the amplification accuracy and sensitivity, the screening is carried out according to the following steps: gradient dilutions were performed using well-defined fully methylated and unmethylated human genomic DNA as template, so that the ratio of sequence of interest to total template was: 50%, 25%, 10%, 5%, 1%, 0.5%, 0.1%. And amplifying by using the templates of the designed multiple sets of alternative primers in each proportion, and setting positive quality control and negative quality control simultaneously. Dividing the amplified product into 2 parts, respectively carrying out agarose gel electrophoresis detection and test strip chromatography system detection, and determining the accuracy and sensitivity of the designed primer.
Experimental results show that after LAMP amplification is carried out on a sample by the optimized primers, the mutation with the proportion as low as 0.1 percent can be detected by using agarose gel electrophoresis and a test strip chromatography system. In addition, the detection signal intensity of the chromatographic test strip for 0.1 percent of the template is judged by naked eyes to be obviously higher than that of agarose gel electrophoresis, and no false positive appears, which is consistent with the expected result.
Example 2 detection of genomic DNA samples
Taking 10 cases of paraffin embedded tissue samples, purifying the genomic DNA, and then treating and converting the genomic DNA by using a modification solution for later use; a, B the following were added to each of the two tubes (methylation specific primer set was added to tube A and unmethylated specific primer set was added to tube B):
the A, B tubes were placed in a metal bath and incubated at 65 ℃ for 30 min.
And (3) respectively dripping the amplification products of the A, B two tubes onto the two test strips, and judging whether mutation is carried out according to the following principle: if the result is shown in FIG. 1, the T line of the test strip corresponding to the A tube methylation specific primer group is developed, and the T line of the test strip corresponding to the B tube non-methylation specific primer group is not developed, the site is completely methylated. As shown in FIG. 2, the test strip corresponding to the A-tube methylation specific primer set shows no color at the T line, and the test strip corresponding to the B-tube methylation specific primer set shows no methylation at the site when the test strip shows color at the T line, and as shown in FIG. 3, the test strips corresponding to the two tubes show color at both the T lines, which shows that the site is partially methylated.
Example 3 detection of free DNA in peripheral blood
Taking 10 fresh samples of peripheral blood, purifying free DNA of the peripheral blood, and treating and converting the peripheral blood with a modifying solution for later use; a, B the following were added to each of the two tubes (methylation specific primer set was added to tube A and unmethylated specific primer set was added to tube B):
the A, B tubes were placed in a metal bath and incubated at 65 ℃ for 30 min.
And (3) respectively dripping the amplification products of the A, B two tubes onto the two test strips, and judging whether mutation is carried out according to the following principle: if the result is shown in FIG. 1, the T line of the test strip corresponding to the A tube methylation specific primer group is developed, and the T line of the test strip corresponding to the B tube non-methylation specific primer group is not developed, the site is completely methylated. As shown in FIG. 2, the test strip corresponding to the A-tube methylation specific primer set shows no color at the T line, and the test strip corresponding to the B-tube methylation specific primer set shows no methylation at the site when the test strip shows color at the T line, and as shown in FIG. 3, the test strips corresponding to the two tubes show color at both the T lines, which shows that the site is partially methylated.
Example 4 detection of free DNA samples from urine
Taking 10 fresh urine samples, purifying free DNA of urine, and treating and converting the urine samples by using a modifying solution for later use; a, B the following were added to each of the two tubes (methylation specific primer set was added to tube A and unmethylated specific primer set was added to tube B):
the A, B tubes were placed in a metal bath and incubated at 65 ℃ for 30 min.
And (3) respectively dripping the amplification products of the A, B two tubes onto the two test strips, and judging whether mutation is carried out according to the following principle: if the result is shown in FIG. 1, the T line of the test strip corresponding to the A tube methylation specific primer group is developed, and the T line of the test strip corresponding to the B tube non-methylation specific primer group is not developed, the site is completely methylated. As shown in FIG. 2, the test strip corresponding to the A-tube methylation specific primer set shows no color at the T line, and the test strip corresponding to the B-tube methylation specific primer set shows no methylation at the site when the test strip shows color at the T line, and as shown in FIG. 3, the test strips corresponding to the two tubes show color at both the T lines, which shows that the site is partially methylated.
While embodiments of the invention have been disclosed above, it is not intended to be limited to the uses set forth in the specification and examples. It can be applied to all kinds of fields suitable for the present invention. Additional modifications will readily occur to those skilled in the art. It is therefore intended that the invention not be limited to the exact details and illustrations described and illustrated herein, but fall within the scope of the appended claims and equivalents thereof.
<110> Xian jin magnetic nanometer biotechnology, Inc
<120> rapid test strip detection method and kit for human miR-34a gene methylation
<160>8
<210> 1
<211>45
<212> DNA
<213>Artificial Sequence
<400> 1
CACGTGAAATTTATTGCGTTGGAGGTCCGTTAGTGCGATGTACCC 45
<210>2
<211>43
<212> DNA
<213>Artificial Sequence
<400>2
ATTGCAAAAATCCAAGAAGCAGCGAGATGTGCCAATCACATAA 43
<210>3
<211>22
<212> DNA
<213>Artificial Sequence
<400>3
GGAGAAAGTGTTGGAGGGTGAA22
<210>4
<211>24
<212> DNA
<213>Artificial Sequence
<400>4
ACTCAAACTAACCATATCACAACA 24
<210>5
<211>52
<212> DNA
<213>Artificial Sequence
<400>5
ACATTAAAACATTACATCAATCGAGGGTTACCGATTAATCCTAGAATGTAA52
<210>6
<211>51
<212> DNA
<213>Artificial Sequence
<400>6
AAATAACCAAACTGGAATTGAACTTATGTGTTAGAAATGTCAAATGTGGTT51
<210>7
<211>22
<212> DNA
<213>Artificial Sequence
<400>7
GGTGGAGAGAATTTGAGGAGGA 22
<210>8
<211>24
<212> DNA
<213>Artificial Sequence
<400>8
CTAAACCCAACTAACATACATCAA 24
Claims (10)
1. A specific primer combination for quickly detecting human miR-34a gene methylation is characterized in that: comprises a methylation specific primer group and an unmethylated specific primer group,
the nucleotide sequences of the methylation specific primer sets are as follows:
the nucleotide sequence of the upstream inner primer FIP in the methylation specific primer group is as follows:
5'-biotin-CACGTGAAATTTATTGCGTTGGAGGTCCGTTAGTGCGATGTACCC
the nucleotide sequence of the downstream inner primer BIP in the methylation specific primer group is as follows:
5'-biotin-ATTGCAAAAATCCAAGAAGCAGCGAGATGTGCCAATCACATAA
the nucleotide sequence of the upstream outer primer F3 in the methylation specific primer group is as follows:
GGAGAAAGTGTTGGAGGGTGAA
the nucleotide sequence of the downstream outer primer B3 in the methylation specific primer group is as follows:
ACTCAAACTAACCATATCACAACA；
the nucleotide sequence of the upstream inner primer FIP in the unmethylated specific primer group is as follows:
5'-biotin-ACATTAAAACATTACATCAATCGAGGGTTACCGATTAATCCTAGAATGTAAG
the nucleotide sequence of the downstream inner primer BIP in the unmethylated specific primer group is as follows:
5'-biotin-AAATAACCAAACTGGAATTGAACTTATGTGTTAGAAATGTCAAATGTGGTT
the nucleotide sequence of the upstream outer primer F3 in the unmethylated specific primer group is as follows: GGTGGAGAGAATTTGAGGAGGA
The nucleotide sequence of the downstream outer primer B3 in the unmethylated specific primer group is as follows: CTAAACCCAACTAACATACATCAA are provided.
2. A kit for quickly detecting methylation of human miR-34a genes is characterized in that: comprising the specific primer combination and the test strip of claim 1.
3. The kit for rapidly detecting methylation of human miR-34a genes according to claim 2, wherein the kit comprises: the quality control line of the test strip is sprayed with goat anti-rabbit IgG for quality control, the detection line is sprayed with streptavidin for capture, and the binding pad is sprayed with digoxin monoclonal antibody modified gold magnetic particles.
4. The kit for rapidly detecting methylation of human miR-34a genes according to claim 3, wherein the kit comprises: the digoxin monoclonal antibody modified gold magnetic particle is a superparamagnetic composite particle with a core-shell structure, the core of the digoxin monoclonal antibody modified gold magnetic particle is a nano Fe3O4 magnetic particle, the surface of the gold magnetic particle is a gold shell layer, and the surface of the gold magnetic particle is modified with digoxin monoclonal antibody to form the digoxin monoclonal antibody modified gold magnetic particle.
5. The kit for rapidly detecting methylation of human miR-34a genes according to claim 4, wherein the kit comprises: the base of digoxin label in the digoxin monoclonal antibody modified on the gold surface is dATP, dTTP, dCTP, dDTP or dUTP.
6. A rapid detection method for human miR-34a gene methylation is characterized by comprising the following steps:
1, obtaining a tissue genome DNA and/or an episome DNA sample;
2, modifying the DNA sample obtained in the step 1 to convert unmethylated cytosine into uracil, wherein the methylated cytosine is not changed;
performing two LAMP reactions in parallel on any one of the samples treated in step 2, wherein the methylation specific primer set of claim 1 is used in one reaction, and the unmethylated specific primer set of claim 1 is used in the other reaction;
adding bases marked by digoxin into two LAMP reaction systems of the same sample to mark amplification products, wherein the two LAMP reaction systems have the same reaction conditions and are simultaneously placed under the constant temperature condition to obtain the amplification products;
and 5, rapidly detecting the amplification product obtained by the treatment in the step 4 by using the test strip in the kit for rapidly detecting the methylation of the human miR-34a gene according to any one of claims 2 to 5, and judging the methylation mode of the sample.
7. The method for rapidly detecting methylation of human miR-34a genes according to claim 6, wherein in the step 1 ], the free DNA sample is peripheral blood free DNA, urine free DNA or other tissue fluid free DNA.
8. The method for rapidly detecting methylation of human miR-34a genes according to claim 6, wherein the modifying solution in the step 2) is 5mM-5M inorganic salt solution or organic solution.
9. The method for rapidly detecting methylation of human miR-34a genes according to claim 8, wherein the inorganic salt solution or the organic solution is a KOH solution, a NaOH solution, a Ca (OH)2 solution, a NaHSO3 solution, a NaHSO4 solution, a Na2SO3 solution or a C6H6O2 solution.
10. The method for rapidly detecting methylation of human miR-34a genes according to claim 8, wherein the step 5 specifically comprises:
dropping the two tubes of amplification products completing the same sample in the step 4 onto sample pads of two test strips respectively for detection, wherein the obtained amplification products are labeled with biotin and digoxin simultaneously, after dropping the amplification products onto the sample pads, the digoxin on the amplification products is specifically combined with the digoxin monoclonal antibody modified gold magnetic particles, and moving up to the detection line in a chromatography manner, the biotin on the amplification products is specifically combined with streptavidin on the detection line for color development, while the reaction solution amplified by the non-methylated specific primers is not developed on the detection line of the test strips, so that complete methylation is indicated; otherwise, the methylation is not carried out; if the detection lines of the two test strips are colored, partial methylation is indicated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011642978.XA CN112553297A (en) | 2020-12-30 | 2020-12-30 | Specific primer combination, kit and method for quickly detecting methylation of human miR-34a gene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011642978.XA CN112553297A (en) | 2020-12-30 | 2020-12-30 | Specific primer combination, kit and method for quickly detecting methylation of human miR-34a gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112553297A true CN112553297A (en) | 2021-03-26 |
Family
ID=75035102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011642978.XA Pending CN112553297A (en) | 2020-12-30 | 2020-12-30 | Specific primer combination, kit and method for quickly detecting methylation of human miR-34a gene |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112553297A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113373204A (en) * | 2021-07-14 | 2021-09-10 | 西安金磁纳米生物技术有限公司 | Specific primer group, kit and method for detecting methylation of human RASSF1A gene |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106498074A (en) * | 2016-11-25 | 2017-03-15 | 金磁（苏州）纳米科技有限公司 | Hands-free cut-off connects the quick ELISA test strip method of people's mthfr gene SNP partings of amplification |
| CN108118081A (en) * | 2016-11-25 | 2018-06-05 | 金磁（苏州）纳米科技有限公司 | Hands-free cut-off connects the quick ELISA test strip method of people's PAH gene SNP partings and kit of amplification |
| WO2019166877A1 (en) * | 2018-03-02 | 2019-09-06 | Sixfold Bioscience Ltd. | Compositions for delivery of cargo to cells |
-
2020
- 2020-12-30 CN CN202011642978.XA patent/CN112553297A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106498074A (en) * | 2016-11-25 | 2017-03-15 | 金磁（苏州）纳米科技有限公司 | Hands-free cut-off connects the quick ELISA test strip method of people's mthfr gene SNP partings of amplification |
| CN108118081A (en) * | 2016-11-25 | 2018-06-05 | 金磁（苏州）纳米科技有限公司 | Hands-free cut-off connects the quick ELISA test strip method of people's PAH gene SNP partings and kit of amplification |
| WO2019166877A1 (en) * | 2018-03-02 | 2019-09-06 | Sixfold Bioscience Ltd. | Compositions for delivery of cargo to cells |
Non-Patent Citations (4)
| Title |
|---|
| DOHWAN LEE ET AL.,: "Simple and Highly Sensitive Molecular Diagnosis of Zika Virus by Lateral Flow Assays", 《ANAL. CHEM.》 * |
| JIN-HEE KIM ET AL.,: "Development of a filtration-based LAMP–LFA method as sensitive and rapid detection of E. coli O157:H7", 《J FOOD SCI TECHNOL》 * |
| MARKUS VOGT ET AL.,: "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas", 《VIRCHOWS ARCH》 * |
| 汪东风等: "《食品质量与安全检测技术》", 31 July 2018, 中国轻工业出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113373204A (en) * | 2021-07-14 | 2021-09-10 | 西安金磁纳米生物技术有限公司 | Specific primer group, kit and method for detecting methylation of human RASSF1A gene |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105821138B (en) | A kind of method that double loop-stem structure DNA profiling detection nucleic acid are built based on coupled reaction | |
| EP3828291A1 (en) | Methylation modification-based tumor marker stamp-ep1 | |
| US20130296328A1 (en) | Epigenetic portraits of human breast cancers | |
| CN109929919B (en) | DNA methylation detection method and related application | |
| EP3828273A1 (en) | Methylation modification-based tumor marker stamp-ep2 | |
| CN113355415B (en) | Detection reagent and kit for diagnosis or auxiliary diagnosis of esophageal cancer | |
| CN106498074A (en) | Hands-free cut-off connects the quick ELISA test strip method of people's mthfr gene SNP partings of amplification | |
| Netto et al. | Diagnostic molecular pathology: current techniques and clinical applications, part I | |
| CN109554476A (en) | Tumor marker STAMP-EP3 based on methylation modification | |
| EP2891719A1 (en) | Test composition for screening cancers | |
| CN110257525A (en) | There is the marker and application thereof of conspicuousness to diagnosing tumor | |
| CN109456968A (en) | Tumor marker STAMP-EP5 based on methylation modification | |
| CN110484621A (en) | A kind of method of liver cancer early warning | |
| CN114410837B (en) | Reagent and kit for detecting HPV18 and application | |
| CN118434885A (en) | Urine miRNA marker for diagnosing bladder cancer, diagnostic reagent and kit | |
| Zhang et al. | All-in-one approaches for rapid and highly specific quantifcation of single nucleotide polymorphisms based on ligase detection reaction using molecular beacons as turn-on probes | |
| WO2019149093A1 (en) | Gene marker for detecting esophageal cancer, use thereof and detection method therefor | |
| CN114381550A (en) | Multi-target nucleic acid detection kit and detection method for HPV typing | |
| CN112553297A (en) | Specific primer combination, kit and method for quickly detecting methylation of human miR-34a gene | |
| CN109652541A (en) | Tumor marker STAMP-EP6 based on methylation modification | |
| CN109371138A (en) | Tumor marker STAMP-EP4 based on methylation modification | |
| CN111440876A (en) | Kit and method for quantitatively detecting methylation degree of human MGMT gene | |
| CN118414427A (en) | Urine miRNA marker for diagnosing prostate cancer, diagnostic reagent and kit | |
| CN109837344A (en) | The EphA7 nucleotide fragments and its detection method of a kind of methylation and application | |
| CN108103178A (en) | The high-throughput detection kit and detection method of neoplastic hematologic disorder fusion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210326 |